Novel Evaluations of Aging and Gender-Affirming Hormone Therapy on Vascular Endothelial Function and Metabolic Profiles in Transgender Women Compared to Age Group-Matched Cisgender Adults

Primary Objective

This study is examining how gender-affirming hormone therapy affects the health of blood vessels and impacts cardiovascular disease risk in transgender women.

Is this Study for You?

Let's Get Started!


Do you qualify? • Transgender women (i. e., assigned male at birth but identify as female) taking estradiol and spironolactone o Ages 18 to 40 or 50 to 75 years o In good general health o Have been on hormones for at least 1 year o No history of gonadectomy o No history of cancer, diabetes or heart disease o Non-smoker (or quit at least one year ago)

Main Procedures Involved: • Blood tests for hormones, cholesterol, clotting factor and other labs • Blood vessel cell collection • Dietary analysis • Physical activity monitor • Questionnaires • Ultrasound of the blood vessels • Measurements of bone mineral density and body composition • Compensation provided



Type of Study





Compensation provided

Principal Investigator
Photograph of Sean Iwamoto,  MD

Sean Iwamoto, MD

Study ID

Protocol Number: 18-2258

More information available at NCT04066283

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers